Elliott Targets Bio-Rad as Shares Continue to Struggle 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Stellantis CEO Antonio Filosa to Reveal Turnaround Strategy Focused on U.S. Sales and China Partnerships 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
REDWOOD CITY, Calif., Sept. 16, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective September 16, 2016, the compensation committee of the company’s board of directors granted 11 new employees options to purchase an aggregate of 127,000 shares of the company’s common stock with a per share exercise price of $30.98, the closing trading price on the grant date. In addition, 100,000 shares of stock were granted to a Senior Vice President, Quality Assurance new hire under the same terms. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O’Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
